Status of malaria vaccine R&D in 2007: Malaria Vaccines for the World 2007, September 17-19th, 2007, London, UK

Expert Review of Vaccines

Volumn 6, Issue 6, 2007, Pages 903-905

  Doolan, Denise L ^a   Stewart, V Ann ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b US Army Medical Research Unit Kenya   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CPG 7909; GAMMA INTERFERON; MALARIA VACCINE; MOSQUIRIX; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; IMMUNIZATION; MALARIA; MALARIA CONTROL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; HUMANS; INTERNATIONALITY; LONDON; MALARIA; MALARIA VACCINES; TECHNOLOGY, PHARMACEUTICAL; WORLD HEALTH;

EID: 37149056558     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.6.903     Document Type: Conference Paper

References (5)

1. Bojang KA. RTS,S/AS02A for malaria. Expert Rev. Vaccines 5(5), 611-615 (2006).
2. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004).
3. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71(2 Suppl.), 1-15 (2004).
4. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030), 214-217 (2005).
5. WHO. World Malaria Report 2005 http://rbm.who.int/wmr2005/index.html